Noninvasive bioluminescence imaging of α-synuclein oligomerization in mouse brain using split firefly luciferase reporters.

Alpha-synuclein (alpha SYN) aggregation plays a pivotal role in the pathogenesis of Parkinson's disease and other synucleinopathies. In this multistep process, oligomerization of alpha SYN monomers is the first step in the formation of fibrils and intracytoplasmic inclusions. Although alpha SYN oligomers are generally considered to be the culprit of these diseases, the methodology currently available to follow-up oligomerization in cells and in brain is inadequate. Wedeveloped a split firefly luciferase complementation system to visualize oligomerization of viral vector-encoded alpha SYN fusion proteins. alpha SYN oligomerization resulted in successful luciferase complementation in cell culture and in mouse brain. Oligomerization of alpha SYN was monitored noninvasively with bioluminescence imaging in the mouse striatum and substantia nigra up to 8 months after injection. Moreover, the visualized alpha SYN oligomers retained their toxic and aggregation properties in both model systems. Next, the effect of two small molecules, FK506 and (-)-epigallocatechin-3-gallate (EGCG), known to inhibit alpha SYN fibril formation, was investigated. FK506 inhibited the observed alpha SYN oligomerization both in cell culture and in mouse brain. In conclusion, the split firefly luciferase-alpha SYN complementation assay will increase our insight in the role of alpha SYN oligomers in synucleinopathies and opens new opportunities to evaluate potential alpha SYN-based neuroprotective therapies.